Prognostic Value of the Largest Lesion Size for Progression-Free Survival in Patients with NET Undergoing Salvage PRRT with [(177)Lu]Lu-DOTATOC

SIMPLE SUMMARY: Peptide receptor radionuclide therapy (PRRT) using radionuclide-labeled somatostatin analogues is based on the overexpression of somatostatin receptors on neuroendocrine tumors and is shown to have a good safety profile and efficacy in different types of metastatic neuroendocrine tum...

Descripción completa

Detalles Bibliográficos
Autores principales: Galler, Markus, Rogasch, Julian M. M., Huang, Kai, Jann, Henning, Plehm, Kristina, Wetz, Christoph, Amthauer, Holger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996884/
https://www.ncbi.nlm.nih.gov/pubmed/35406540
http://dx.doi.org/10.3390/cancers14071768

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996884/
https://www.ncbi.nlm.nih.gov/pubmed/35406540
http://dx.doi.org/10.3390/cancers14071768

Ejemplares similares